Liu Baodong, Liu Lei, Li Yan, Wang Hong, Hu Mu, Qian Kun, Wang Ruotian, Zhi Xiuyi
Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Zhongguo Fei Ai Za Zhi. 2011 Apr;14(4):335-9. doi: 10.3779/j.issn.1009-3419.2011.04.06.
Surgical resection is the preferred treatment in selected patients with pulmonary neoplasms. In older than 70 years or have compromised cardiopulmonary status or coexistent medical problems patients, radiofrequency ablation (RFA) may offer an alternative option. The aim of this study is to evaluate the therapeutic effects after RFA in 100 patients with pulmonary neoplasms.
One hundred cases of unresectable lung tumors with 106 lesions were underwent RFA therapy. To evaluate the therapeutic effect and complications of lung tumors using spiral CT scanning and SPECT in 1-3 months after RFA.
One hundred patients underwent RFA for lung neoplasms (62 men, 38 women; median age, 66.6 years; range, 36 to 91 years). Eighty-six patients with primary lung neoplasms and 14 patients with pulmonary metastases underwent RFA. Treatment was complete in all cases, no treatment-related deaths occurred in all of the 100 patients and serious morbidity associated with the procedures. The median overall survival for the entire group of patients was 13.0 months, the one and two years overall survival for total of were 51% and 32.5% respectively. No differences in overall survival noted between patients with primary and metastases lung neoplasms (P=0.922). The median overall survival for the early stage of patients was 28.0 months, 2-year overall survival for early stage primary lung cancer patients were 57.7%.
RFA is a safe and effective procedure in selective lung tumors. CT-guided radiofrequency ablation is a minimally invasive treatment option. RFA could act as an alternative treatment to inoperable lung cancer.
手术切除是部分肺部肿瘤患者的首选治疗方法。对于70岁以上、心肺功能受损或伴有其他内科疾病的患者,射频消融(RFA)可能是一种替代选择。本研究旨在评估100例肺部肿瘤患者接受RFA治疗后的疗效。
对100例无法切除的肺部肿瘤患者的106个病灶进行RFA治疗。在RFA治疗后1至3个月,使用螺旋CT扫描和SPECT评估肺部肿瘤的治疗效果及并发症。
100例患者接受了肺部肿瘤的RFA治疗(男性62例,女性38例;中位年龄66.6岁;范围36至91岁)。86例原发性肺部肿瘤患者和14例肺转移患者接受了RFA治疗。所有病例治疗均完成,100例患者中无治疗相关死亡及与手术相关的严重并发症发生。整个患者组的中位总生存期为13.0个月,1年和2年总生存率分别为51%和32.5%。原发性和转移性肺部肿瘤患者的总生存期无差异(P=0.922)。早期患者的中位总生存期为28.0个月,早期原发性肺癌患者的2年总生存率为57.7%。
RFA对选择性肺部肿瘤是一种安全有效的治疗方法。CT引导下的射频消融是一种微创治疗选择。RFA可作为无法手术切除肺癌的替代治疗方法。